Correlation Between Bristol Myers and Oric Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Oric Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Oric Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and Oric Pharmaceuticals, you can compare the effects of market volatilities on Bristol Myers and Oric Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Oric Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Oric Pharmaceuticals.

Diversification Opportunities for Bristol Myers and Oric Pharmaceuticals

-0.26
  Correlation Coefficient

Very good diversification

The 3 months correlation between Bristol and Oric is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Oric Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oric Pharmaceuticals and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Oric Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oric Pharmaceuticals has no effect on the direction of Bristol Myers i.e., Bristol Myers and Oric Pharmaceuticals go up and down completely randomly.

Pair Corralation between Bristol Myers and Oric Pharmaceuticals

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.37 times more return on investment than Oric Pharmaceuticals. However, Bristol Myers Squibb is 2.68 times less risky than Oric Pharmaceuticals. It trades about -0.09 of its potential returns per unit of risk. Oric Pharmaceuticals is currently generating about -0.19 per unit of risk. If you would invest  5,887  in Bristol Myers Squibb on September 23, 2024 and sell it today you would lose (154.00) from holding Bristol Myers Squibb or give up 2.62% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Bristol Myers Squibb  vs.  Oric Pharmaceuticals

 Performance 
       Timeline  
Bristol Myers Squibb 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady primary indicators, Bristol Myers showed solid returns over the last few months and may actually be approaching a breakup point.
Oric Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oric Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Bristol Myers and Oric Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bristol Myers and Oric Pharmaceuticals

The main advantage of trading using opposite Bristol Myers and Oric Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Oric Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oric Pharmaceuticals will offset losses from the drop in Oric Pharmaceuticals' long position.
The idea behind Bristol Myers Squibb and Oric Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio